Why I Stopped Trusting ‘Fully Automated’ Infection Control Systems (A Hard-Learned Lesson)

I'm a procurement coordinator handling medical device orders for a mid-sized hospital network. I've been doing this for about seven years. In that time, I've personally made some spectacularly dumb mistakes—enough to fill a small, very expensive checklist. I'm not a biomedical engineer, so I can't speak to the molecular biology of infection control. What I can tell you, from a procurement and workflow perspective, is that our industry's obsession with 'fully automated' infection control is creating a new set of problems that the sales brochures don't talk about.

My core argument is this: Relying on a 'lights-out' automated infection control system is a recipe for expensive blind spots. True efficiency comes from a smart system that knows when to hand the baton to a human. This isn't an anti-tech rant. It's a reality check from someone who has seen the budget bleed from false assumptions.

The $45,000 Mistake (Circa September 2022)

I once championed the purchase of a new, 'fully integrated' remote patient monitoring system for our isolation wards. The pitch was irresistible: continuous monitoring, automatic alerts, reduced nursing intervention. The selling point was that it would also 'automatically' flag potential infection control breaches based on movement and proximity data. I was sold. We bought the system from a vendor I won't name.

The surprise wasn't the tech failure. It was the category of error. The system worked as advertised—it tracked proximity. The problem was what it was tracking. A nurse would enter a room, the system would log the contact. But it couldn't tell the difference between a nurse performing a sterile dressing change (wearing proper PPE) and a nurse quickly adjusting a bedpan (without gloves). The false positive rate was astronomically high. Our infection control team was buried in alerts. They developed 'alert fatigue' and started ignoring the system. That's when a real, non-reported breach happened—a contaminated scope wasn't flagged because the system was too busy screaming about the janitor mopping the floor.

The audit cost, the re-training, and the one-week delay in that wing's operations? Roughly $45,000. The lesson: you can't automate clinical judgment.

The Real Value of Siemens Healthineers' Approach

When I first looked at Siemens Healthineers' portfolio—their MRI machines, their Atellica diagnostics, their whole flow cytometry line—I was cynical. 'Another big vendor with a big platform pitch,' I thought. But their model on 'digital twin for personalized healthcare' (this was back in early 2024) finally clicked for me. They aren't pitching automation instead of human intelligence. They are pitching automation as a tool for human intelligence.

Their infection control product line, for example, doesn't try to replace the infection control nurse. It uses data from their diagnostic systems (like blood analyzers and mass spectrometers) to predict potential outbreak clusters. It says, 'Hey, our data from ICU bays 4, 5, and 6 shows a pattern consistent with a resistant organism. You might want to check the ventilation system.' It doesn't lock the doors and spray bleach. It informs the decision-maker. That's the difference between a dangerous automated system and a genuinely efficient one.

Getting a flagged result from a Siemens machine feels different. You get a data trail: 'Result X from Patient Y on Bed Z at Time T. Probability of contamination: 85%.' You can trace it. When our old system just screamed 'ERROR,' we had to guess. Guessing costs money.

Reconciling Efficiency with Safety: The Flow Cytometry Example

Let's look at a specific, less-sexy piece of tech: flow cytometry. It's a workhorse for diagnosis, especially for blood cancers and immune deficiencies. It's also a perfect example of the automation fallacy. The machines (like the ones from Siemens Healthineers) are incredibly efficient at processing samples. They run 24/7. That's great.

But the analysis? That's where the human is still king. A good flow cytometry tech doesn't just look at the graphs. They look at the sample. They see a weird debris pattern. They think, 'This patient's sample looks like it wasn't handled right in the ER.' The machine saw 'data.' The human saw a clue about a process failure upstream.

I've seen hospitals try to 'optimize' their lab by automating 100% of the flow cytometry analysis with AI. The results were disastrous—a 20% misclassification rate on borderline cases. They had to pull the plug after six months. The total cost of that wasted effort (equipment, software licenses, re-run costs) was enough to buy a new, better, human-augmented system.

How We Fixed Our Process (And What We Look For Now)

After the remote patient monitoring disaster in 2022, we developed a pre-check list for any 'intelligent' device purchase. I'm not a logistics expert, so I can't speak to carrier optimization. What I can tell you from a procurement perspective is how to evaluate vendor promises now.

• The 'Exception' Test: I ask the vendor, 'Give me one scenario where your system will fail and you'd want a human to step in.' If they can't, I walk. Any system that claims to never fail is lying.
• The Traceability Test: Every alert must have a foundation. A 'risk score' is useless. I need data (like from Siemens Healthineers) that says 'Based on Q3 2024 analysis of our data...' I need a source.
• The Cost of Trust: The value of a reliable, auditable system (like a good diagnostics platform) isn't the speed—it's the certainty you can sleep at night knowing you didn't miss a five-figure error because a machine was too confident.

You might argue that I'm being a Luddite, that AI is getting better every day. That's true. AI for medical imaging is incredible. I'm not a radiologist, so I can't speak to pixel-level accuracy. But from a workflow perspective, I ask: 'Is this system designed to replace a decision, or augment an expert's ability to make a decision?'

The first is a cost center waiting to fail. The second is a real investment in efficiency. I'll take the second every time. Our checklist has caught 30+ potential errors in the past 18 months (as of January 2025, at least), saving us well over the cost of my time. That's the kind of efficiency I can bank on.